Vivos Therapeutics (VVOS) Fireside Chat summary
Event summary combining transcript, slides, and related documents.
Fireside Chat summary
17 Dec, 2025Introduction and agenda
2025 marked a pivotal year with a transformative business model shift, highlighted by the acquisition of Sleep Center of Nevada (SCN) in June.
Background and experience of the speaker
The team has deep experience in dental support organizations and operating medical-dental practices, leveraging this expertise for the new model.
Current industry trends
Obstructive sleep apnea is a major health crisis, with CPAP as the longstanding but unpopular standard treatment.
Home sleep testing is driving a surge in diagnoses, with nearly three million tests expected this year and a growing millennial patient base.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Vivos Therapeutics
- Registers 3.96M shares for resale, supporting a shift to sleep center acquisitions in the OSA market.VVOS
Registration Filing17 Feb 2026 - Q2 2024 revenue up 19%, net loss narrowed, but liquidity and going concern risks persist.VVOS
Q2 20241 Feb 2026 - Q3 revenue up 17%, gross margin at 60%, and new alliances and FDA clearance drive outlook.VVOS
Q3 202413 Jan 2026 - Strategic shift to direct medical engagement and new alliances set stage for major growth in 2025.VVOS
Fireside Chat24 Dec 2025 - Revenue up 9%, operating loss down 35%, with alliances and FDA clearances fueling 2025 growth.VVOS
Q4 202419 Dec 2025 - Registers resale of shares/warrants from $7.5M private placement, supporting new alliance-based OSA distribution model.VVOS
Registration Filing16 Dec 2025 - Registering up to $50M in securities to expand FDA-cleared OSA solutions and accelerate growth.VVOS
Registration Filing16 Dec 2025 - Offering up to $50M in securities to expand sleep apnea treatment via alliances and acquisitions.VVOS
Registration Filing16 Dec 2025 - Key votes include director elections, new equity plan approval, and auditor ratification.VVOS
Proxy Filing1 Dec 2025